215 related articles for article (PubMed ID: 12363043)
1. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer.
Zaffaroni N; Pennati M; Colella G; Perego P; Supino R; Gatti L; Pilotti S; Zunino F; Daidone MG
Cell Mol Life Sci; 2002 Aug; 59(8):1406-12. PubMed ID: 12363043
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Kelland LR; Abel G
Cancer Chemother Pharmacol; 1992; 30(6):444-50. PubMed ID: 1356649
[TBL] [Abstract][Full Text] [Related]
3. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells.
Wang Z; Xie Y; Wang H
Cancer Biol Ther; 2005 Jul; 4(7):716-9. PubMed ID: 15970709
[TBL] [Abstract][Full Text] [Related]
4. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
Zhou J; O'brate A; Zelnak A; Giannakakou P
Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
[TBL] [Abstract][Full Text] [Related]
5. [RNA interference silencing expression of survivin gene and reversing drug resistance of ovarian cancer cell line SKOV3/ADM].
Deng KX; Zhong L; Jiang MX; Wang PL; Chen Y
Zhonghua Fu Chan Ke Za Zhi; 2005 Dec; 40(12):836-9. PubMed ID: 16412331
[TBL] [Abstract][Full Text] [Related]
6. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells.
Carvalho A; Carmena M; Sambade C; Earnshaw WC; Wheatley SP
J Cell Sci; 2003 Jul; 116(Pt 14):2987-98. PubMed ID: 12783991
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
[TBL] [Abstract][Full Text] [Related]
8. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
[TBL] [Abstract][Full Text] [Related]
9. [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].
Yan XJ; Liang LZ; Zeng ZY; Shi Z; Fu LW
Ai Zheng; 2006 Apr; 25(4):398-403. PubMed ID: 16613669
[TBL] [Abstract][Full Text] [Related]
10. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest.
Ling X; Bernacki RJ; Brattain MG; Li F
J Biol Chem; 2004 Apr; 279(15):15196-203. PubMed ID: 14722122
[TBL] [Abstract][Full Text] [Related]
11. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Yamamoto K; Kikuchi Y; Kudoh K; Nagata I
J Cancer Res Clin Oncol; 2000 Mar; 126(3):168-72. PubMed ID: 10741911
[TBL] [Abstract][Full Text] [Related]
12. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells.
Braakhuis BJ; Hill BT; Dietel M; Kelland LR; Aapro MS; Zoli W; Lelieveld P
Anticancer Res; 1994; 14(1A):205-8. PubMed ID: 7909419
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.
Pennati M; Campbell AJ; Curto M; Binda M; Cheng Y; Wang LZ; Curtin N; Golding BT; Griffin RJ; Hardcastle IR; Henderson A; Zaffaroni N; Newell DR
Mol Cancer Ther; 2005 Sep; 4(9):1328-37. PubMed ID: 16170024
[TBL] [Abstract][Full Text] [Related]
15. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F
Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
[TBL] [Abstract][Full Text] [Related]
16. In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer.
Silvestrini R; Zaffaroni N; Orlandi L; Oriana S
Stem Cells; 1993 Nov; 11(6):528-35. PubMed ID: 7906583
[TBL] [Abstract][Full Text] [Related]
17. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
Anticancer Res; 2003; 23(2B):1525-31. PubMed ID: 12820419
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.
Busschots S; O'Toole S; O'Leary JJ; Stordal B
Exp Cell Res; 2015 Aug; 336(1):1-14. PubMed ID: 25499884
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
[TBL] [Abstract][Full Text] [Related]
20. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
Nomura T; Yamasaki M; Nomura Y; Mimata H
Oncol Rep; 2005 Oct; 14(4):993-7. PubMed ID: 16142363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
